Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Cancer Res. 2017 Jun 27;23(19):5745–5756. doi: 10.1158/1078-0432.CCR-16-2844

Fig 3. Repeatability of ADCL measurements, consistency of resulting ADCL phenotypes for different thresholds, and optimal thresholds for predicting overall survival (OS) in recurrent GBM treated with anti-VEGF therapies.

Fig 3

A) Repeated diffusion MR measures of ADCL in recurrent GBM using “double baseline”, repeated pre-treatment examinations, from the cediranib trial. B) Repeatability of ADCL phenotypes (e.g. higher vs. lower ADCL) for different thresholds (solid black line, left y-axis) as well as the proportion of patients higher or lower than this threshold (gray lines, right y-axis). C) Mantel-Haenszel hazard ratios (HRs, solid black line) and 95% confidence intervals (gray area) for OS in recurrent GBM for different ADCL thresholds in patients pooled from all four anti-VEGF therapies. D) Level of significance (p-values) for OS differences for different ADCL thresholds in patients pooled from all four anti-VEGF therapies. E) Mantel-Haenszel HRs for OS for different ADCL thresholds for individual anti-VEGF therapies. F) Level of significance (p-values) for OS differences for ADCL thresholds in individual anti-VEGF therapies.